Fig. 1From: Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized studyPatient disposition. Two patients (one in the BGF MDI group and one in the BFF MDI group) participated in multiple sponsor-led studies and were excluded from all analysis populations. BFF Budesonide/formoterol fumarate, BGF Budesonide/glycopyrrolate/formoterol fumarate, BMD Bone mineral density, GFF Glycopyrrolate/formoterol fumarate, MDI Metered dose inhalerBack to article page